Gilad S. Gordon

Costs, effects and C/E‐ratios alongside a clinical trial

Ben A. van Hout, Maiwenn Al, Gilad S. Gordon et al. · Health Economics · 1994 · 981 citations

Pharmacy, Pharmacoeconomics, Pharmacotherapy +15

Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral, Small-Molecule Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor AZD6244 (ARRY-142886) in Patients With Advanced Cancers

Alex A. Adjei, Roger B. Cohen, Wilbur A. Franklin et al. · Journal of Clinical Oncology · 2008 · 573 citations · Full text

Medicine, Oncology, Pharmacology +17

Nasal absorption of insulin: enhancement by hydrophobic bile salts.

Gilad S. Gordon, A C Moses, Robert D. Silver et al. · Proceedings of the National Academy of Sciences · 1985 · 278 citations · Full text

Pharmacy, Biochemistry, Pharmacology +16

Insulin Administered Intranasally as an Insulin-Bile Salt Aerosol: Effectiveness and Reproducibility in Normal and Diabetic Subjects

Alan C. Moses, Gilad S. Gordon, Martin C. Carey et al. · Diabetes · 1983 · 195 citations

Medicine, Endocrinology, Pharmacology +14

Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised, placebo-controlled, phase 1 study

Jorge E. Osorio, Iván Darío Vélez, Cynthia A. Thomson et al. · The Lancet Infectious Diseases · 2014 · 151 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +10